JP2017536354A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536354A5 JP2017536354A5 JP2017523975A JP2017523975A JP2017536354A5 JP 2017536354 A5 JP2017536354 A5 JP 2017536354A5 JP 2017523975 A JP2017523975 A JP 2017523975A JP 2017523975 A JP2017523975 A JP 2017523975A JP 2017536354 A5 JP2017536354 A5 JP 2017536354A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- item
- seq
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims description 33
- 108010056852 Myostatin Proteins 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 21
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 16
- 208000021642 Muscular disease Diseases 0.000 claims description 13
- 201000009623 Myopathy Diseases 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 230000008105 immune reaction Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 230000017854 proteolysis Effects 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 3
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 230000009918 complex formation Effects 0.000 claims description 2
- 238000010494 dissociation reaction Methods 0.000 claims description 2
- 230000005593 dissociations Effects 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010023082 activin A Proteins 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 108010059616 Activins Proteins 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 102100026818 Inhibin beta E chain Human genes 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000002638 denervation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000891 luminescent agent Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076230P | 2014-11-06 | 2014-11-06 | |
| US62/076,230 | 2014-11-06 | ||
| US201562100361P | 2015-01-06 | 2015-01-06 | |
| US62/100,361 | 2015-01-06 | ||
| US201562187348P | 2015-07-01 | 2015-07-01 | |
| US62/187,348 | 2015-07-01 | ||
| US201562219094P | 2015-09-15 | 2015-09-15 | |
| US62/219,094 | 2015-09-15 | ||
| PCT/US2015/059468 WO2016073853A1 (en) | 2014-11-06 | 2015-11-06 | Anti-pro/latent-myostatin antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020085618A Division JP2020127430A (ja) | 2014-11-06 | 2020-05-15 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536354A JP2017536354A (ja) | 2017-12-07 |
| JP2017536354A5 true JP2017536354A5 (enExample) | 2018-12-13 |
| JP6706617B2 JP6706617B2 (ja) | 2020-06-10 |
Family
ID=55909861
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523975A Active JP6706617B2 (ja) | 2014-11-06 | 2015-11-06 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| JP2020085618A Withdrawn JP2020127430A (ja) | 2014-11-06 | 2020-05-15 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| JP2022130847A Pending JP2022166238A (ja) | 2014-11-06 | 2022-08-19 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
| JP2024077058A Pending JP2024109663A (ja) | 2014-11-06 | 2024-05-10 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020085618A Withdrawn JP2020127430A (ja) | 2014-11-06 | 2020-05-15 | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| JP2022130847A Pending JP2022166238A (ja) | 2014-11-06 | 2022-08-19 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
| JP2024077058A Pending JP2024109663A (ja) | 2014-11-06 | 2024-05-10 | 抗プロ／潜在型－ミオスタチン抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10307480B2 (enExample) |
| EP (1) | EP3215175A4 (enExample) |
| JP (4) | JP6706617B2 (enExample) |
| AU (3) | AU2015342936B2 (enExample) |
| CA (1) | CA3005158A1 (enExample) |
| HK (1) | HK1243940A1 (enExample) |
| WO (1) | WO2016073853A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4793360A2 (en) | 2006-03-31 | 2026-08-19 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| CA2865158C (en) | 2012-02-24 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| IL254039B2 (en) | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| EA038146B1 (ru) * | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| EA201891420A1 (ru) * | 2015-12-18 | 2019-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE |
| CN115814077A (zh) * | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| PL4218804T3 (pl) | 2016-06-13 | 2026-05-25 | Scholar Rock, Inc. | Stosowanie inhibitorów miostatyny i terapii skojarzonych |
| TWI760396B (zh) * | 2016-06-17 | 2022-04-11 | 日商中外製藥股份有限公司 | 抗肌抑素抗體及使用方法 |
| CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| KR102585976B1 (ko) | 2016-08-17 | 2023-10-05 | 컴퓨젠 엘티디. | 항-tigit 항체, 항-pvrig 항체 및 이들의 조합 |
| WO2018129395A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| HRP20230308T1 (hr) * | 2017-01-06 | 2023-05-12 | Scholar Rock, Inc. | Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina |
| PT3677278T (pt) | 2018-07-11 | 2022-02-03 | Scholar Rock Inc | Inibidores seletivos da isoforma tgfbeta1 e sua utilização |
| KR102891320B1 (ko) | 2018-07-11 | 2025-11-28 | 스칼러 락, 인크. | 고친화도, 이소형-선택적 TGFβ1 억제제 및 그의 용도 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| DK4358995T3 (da) | 2021-06-23 | 2026-02-02 | Scholar Rock Inc | Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser |
| US20260159579A1 (en) * | 2021-11-02 | 2026-06-11 | Pfizer Inc. | Methods of treating mitochondrial myopathies using anti-gdf15 antibodies |
| CN114891101B (zh) * | 2021-12-02 | 2023-06-16 | 吉林省农业科学院 | 一种牛肌肉生长抑制素蛋白单克隆抗体及其应用 |
| CN120677175A (zh) | 2022-12-22 | 2025-09-19 | 供石公司 | 肌生成抑制蛋白活化的选择性和强效抑制剂 |
| EP4676954A1 (en) | 2023-03-07 | 2026-01-14 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
| WO2025245160A1 (en) | 2024-05-21 | 2025-11-27 | Scholar Rock, Inc. | Myostatin-selective inhibitors for treating metabolic disorders |
| TW202617762A (zh) * | 2024-07-04 | 2026-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合潛伏肌生長抑制素的抗原結合分子及其醫藥用途 |
| WO2026147753A1 (en) | 2024-12-30 | 2026-07-09 | Scholar Rock, Inc. | Therapies for muscular dystrophies |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| DE69534468T2 (de) | 1994-07-08 | 2006-07-13 | The Johns Hopkins University School Of Medicine | Wachstums-differenzierungsfaktor-11 |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| FR2804102B1 (fr) | 2000-01-26 | 2002-08-16 | Rhodia Terres Rares | Dispersion colloidale aqueuse d'un compose de cerium et d'au moins un autre element choisi parmi les terres rares, des metaux de transition, l'aluminium, le gallium et le zirconium, procede de preparation et utilisation |
| PL357017A1 (en) | 2000-01-28 | 2004-07-12 | Novo Nordisk A/S | Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| AU2001268427B2 (en) * | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| AU2011244851A1 (en) * | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| ATE364632T1 (de) * | 2001-10-05 | 2007-07-15 | Affimed Therapeutics Ag | Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| US20040044063A1 (en) | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
| US20040131614A1 (en) | 2002-07-19 | 2004-07-08 | Abbott Biotechnology Ltd. | Treatment of pulmonary disorders using TNFalpha inhibitor |
| AU2003267246A1 (en) | 2002-09-16 | 2004-04-30 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| JP4754219B2 (ja) * | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| AU2003301195B2 (en) | 2002-12-20 | 2010-01-07 | Amgen Inc. | Binding agents which inhibit myostatin |
| WO2005066204A2 (en) | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| CA2558478A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
| US20070178095A1 (en) | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| EP1755648A2 (en) | 2004-05-27 | 2007-02-28 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| EP2361933A3 (en) * | 2005-01-26 | 2012-05-02 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| TW200724548A (en) | 2005-04-25 | 2007-07-01 | Pfizer | Antibodies to myostatin |
| US7888486B2 (en) | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| KR101135220B1 (ko) | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| KR20070105685A (ko) | 2006-04-27 | 2007-10-31 | 영남대학교 산학협력단 | 메트포르민을 포함하는 비만치료용 조성물 |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| BRPI0715072A2 (pt) | 2006-08-03 | 2013-06-25 | Orico Ltd | antagonistas de miostatina |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| HRP20130320T1 (en) * | 2006-09-05 | 2013-05-31 | Eli Lilly And Company | Anti-myostatin antibodies |
| WO2008067480A2 (en) | 2006-11-29 | 2008-06-05 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| KR101531722B1 (ko) | 2007-03-30 | 2015-06-25 | 메르크 파텐트 게엠베하 | 음성 광학 분산도를 갖는 복굴절층 |
| AU2008260445A1 (en) | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| CA2722418C (en) * | 2008-05-13 | 2013-09-17 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| TW201029662A (en) | 2008-12-19 | 2010-08-16 | Glaxo Group Ltd | Novel antigen binding proteins |
| US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| JP2012520887A (ja) * | 2009-03-18 | 2012-09-10 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物 |
| ES2655877T3 (es) | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| US8945511B2 (en) | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
| NZ599604A (en) | 2009-10-01 | 2014-07-25 | Myostin Therapeutics Pty Ltd | Synthetic myostatin peptide antagonists |
| EP3904391B1 (en) | 2010-03-10 | 2024-07-10 | Genmab A/S | Monoclonal antibodies against c-met |
| TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| AR081556A1 (es) | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
| PH12013500315A1 (en) | 2010-08-16 | 2013-04-29 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| WO2013071056A2 (en) | 2011-11-11 | 2013-05-16 | Duke University | Combination drug therapy for the treatment of solid tumors |
| SMT201800092T1 (it) * | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| US20150284455A1 (en) * | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
| BR112015027336A2 (pt) | 2013-05-01 | 2017-09-26 | Genzyme Corp | composições e processos para tratamento de atrofia muscular espinhal |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| EP2853898B1 (en) * | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| US10004814B2 (en) | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| MX2017005774A (es) * | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| EA038146B1 (ru) | 2015-09-15 | 2021-07-13 | Сколар Рок, Инк. | Антитела к про-/латентному миостатину и их применения |
| EA201891420A1 (ru) | 2015-12-18 | 2019-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| PL4218804T3 (pl) | 2016-06-13 | 2026-05-25 | Scholar Rock, Inc. | Stosowanie inhibitorów miostatyny i terapii skojarzonych |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| WO2018129395A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| HRP20230308T1 (hr) | 2017-01-06 | 2023-05-12 | Scholar Rock, Inc. | Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina |
| US20210087250A1 (en) | 2018-04-06 | 2021-03-25 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| SG11202108099WA (en) | 2019-01-30 | 2021-08-30 | Scholar Rock Inc | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF |
| EP4232151B1 (en) | 2020-10-26 | 2025-10-22 | Scholar Rock, Inc. | Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy |
| CN117545842A (zh) | 2021-01-29 | 2024-02-09 | 拜奥卡德联合股份公司 | SMN1和miR-23a在治疗脊髓性肌萎缩中的协同效应 |
| DK4358995T3 (da) | 2021-06-23 | 2026-02-02 | Scholar Rock Inc | Myostatin-vej-hæmmer i kombination med en glp-1-vej-aktivator til brug ved behandling af metaboliske forstyrrelser |
| LT4518970T (lt) | 2022-05-04 | 2026-04-27 | Scholar Rock, Inc. | Miostatino inhibitoriaus panaudojimas spinalinės raumenų atrofijos gydymui |
| JP2025532651A (ja) | 2022-09-21 | 2025-10-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 肥満、糖尿病および肝機能障害を処置する方法 |
| CN120677175A (zh) | 2022-12-22 | 2025-09-19 | 供石公司 | 肌生成抑制蛋白活化的选择性和强效抑制剂 |
-
2015
- 2015-11-06 WO PCT/US2015/059468 patent/WO2016073853A1/en not_active Ceased
- 2015-11-06 AU AU2015342936A patent/AU2015342936B2/en active Active
- 2015-11-06 US US15/524,651 patent/US10307480B2/en active Active
- 2015-11-06 HK HK18103508.9A patent/HK1243940A1/zh unknown
- 2015-11-06 EP EP15857125.7A patent/EP3215175A4/en active Pending
- 2015-11-06 CA CA3005158A patent/CA3005158A1/en active Pending
- 2015-11-06 JP JP2017523975A patent/JP6706617B2/ja active Active
-
2019
- 2019-04-04 US US16/374,854 patent/US11135291B2/en active Active
-
2020
- 2020-05-15 JP JP2020085618A patent/JP2020127430A/ja not_active Withdrawn
- 2020-12-22 AU AU2020294193A patent/AU2020294193B2/en active Active
-
2021
- 2021-09-03 US US17/446,897 patent/US11925683B2/en active Active
-
2022
- 2022-08-19 JP JP2022130847A patent/JP2022166238A/ja active Pending
-
2024
- 2024-02-02 US US18/431,294 patent/US12661400B2/en active Active
- 2024-05-10 JP JP2024077058A patent/JP2024109663A/ja active Pending
- 2024-05-14 AU AU2024203178A patent/AU2024203178A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7854016B2 (ja) | 腫瘍治療薬及びその応用 | |
| US11925683B2 (en) | Compositions for making and using anti-Myostatin antibodies | |
| CN114341186B (zh) | 双特异性抗LRRC15和CD3ε抗体 | |
| CN107922503B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| JP2026035721A (ja) | 抗プロ／潜在型ミオスタチン抗体およびその使用 | |
| JP2019527194A5 (enExample) | ||
| AU2015228454A1 (en) | Anti-MCAM antibodies and associated methods of use | |
| WO2013183786A1 (ja) | トランスポーターに対する抗体およびその用途 | |
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
| EP4292611A1 (en) | Anti-cd112r antibody and use thereof | |
| CA3208455A1 (en) | Novel anti-gremlin1 antibodies | |
| JP2021511387A5 (enExample) | ||
| WO2020034941A1 (zh) | 抗IL-1β的抗体、其药物组合物及其用途 | |
| TW202214303A (zh) | 用於癌症治療之結合分子 | |
| WO2020169062A1 (zh) | 抗pd-l1抗体及其用途 | |
| KR20230034367A (ko) | 항-종양 괴사 인자 수용체 (tnfr2) 항체 및 그 용도 | |
| TW202506733A (zh) | 淋巴毒素β受體促效劑結合蛋白 | |
| KR20260068079A (ko) | Igf-1r 및 tshr 결합 단백질 및 이의 의약적 용도 | |
| CN108064250A (zh) | 抗-cd20-/抗-baff双特异性抗体 | |
| AU2023375570A1 (en) | Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof | |
| TW202523697A (zh) | 抗ｔｓｌｐ抗體構築體及其用途 | |
| TW202537974A (zh) | Ｔｒｇｖ９結合蛋白及其醫藥用途 | |
| KR20260062948A (ko) | Ctla4/tigit 결합 단백질 및 이의 의학적 용도 | |
| HK40093421A (zh) | 新颖的抗gremlin1抗体 | |
| HK40089230A (en) | Pharmaceutical composition and use |